![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Aim: Albendazole (ABZ) is a broad-spectrum antiparasitic agent with poor aqueous solubility, which leads to poor/erratic bioavailability and therapeutic failures. Here, we aimed to produce a novel formulation of ABZ nanocrystals (ABZNC) and assess its pharmacokinetic performance in mice. Results/methodology: ABZNC were prepared by high-pressure homogenization and spray-drying processes. Redispersion capacity and solid yield were measured in order to obtain an optimized product. The final particle size was 415.69±7.40 nm and the solid yield was 72.32%. The pharmacokinetic parameters obtained in a mice model for ABZNC were enhanced (p < 0.05) with respect to the control formulation. Conclusion: ABZNC with improved pharmacokinetic behavior were produced by a simple, inexpensive and potentially scalable methodology.
Acknowledgements
The technical assistance of C Farías from CIVETAN in the processing of HPLC samples is also acknowledged.
Financial & competing interests disclosure
The authors wish to acknowledge the assistance, the financial support and facilities from the National Scientific and Technical Research Council (CONICET), National University of Central Buenos Aires and National University of Córdoba. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The protocols for animal procedures and management were approved by the Ethics Committee according to the Animal Welfare Policy of the Faculty of Veterinary Medicine, National University of Central Buenos Aires, Tandil, Argentina (www.vet.unicen.edu.ar).